CVR Medical names new VP of sales

CVR Medical's Carotid Stenotic Scanner

Vancouver-based medical monitoring systems company CVR Medical has recruited a seasoned technology industry executive to become the company’s new vice-president of sales and marketing.

Alan Langston will be responsible for creating and implementing market entry strategies for the CVR Medical’s “Carotid Stenotic Scan (CSS)” device. The CSS is the company’s brand-new technology which is used for detecting Ischemia – one of the main indicators of a potential stroke.

Alan Langston

Langston experience encompasses covering a broad spectrum of the tech industry in the sales, marketing, and distribution channels. He has worked with leading global manufacturers and OEMs such as Kontron America, Panasonic, Arrow Electronics, Avnet, GE, Siemens, and Philips.

During his tenure at Kontron America, the second-leading global embedded computer supplier, annual channel sales figures grew from $12M to $41M. While with Panasonic’s Toughbook division, Langston oversaw similar results, taking new independent software vendors (ISVs) groups from $0 to $4M in new opportunities within twelve months.

Langston has served as a consultant for CVR, becoming well-versed with the CSS and the cardiovascular healthcare landscape over the past decade. As the CSS launch rapidly approaches, he has opted to make a full-time commitment to CVR.

The main equipment for detecting early signs of strokes is the CT scanner which can cost up to $2.5 million.

The planned price for the CSS is just $49,000 per unit, according to the financial site, Baystreet.ca.

The CSS monitors for signs of stenosis within the arteries. Stenosis is an indicator of Ischemia. The CSS analyzes the wave patterns and pinpoints potential trouble spots.

“After ten years of consistently consulting with CVR and watching this product evolve, I feel that everything is aligned perfectly for both me and the company to move forward together,” said Langston. “This is one of the most remarkable devices to become available to the medical community in a long time.”

Be the first to comment

Leave a Reply

Your email address will not be published.


*